{"groups":[{"description":"Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.","id":"FG000","title":"High-Risk Hematologic Malignancies"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Met Exclusion Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Muromonab not available"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Health Status Change"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"37"}],"type":"Non-Patient Donors"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"73"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"31"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"There were 73 enrollments at St. Jude Children's Research Hospital between 12/2007 and 12/2013. Of the 73, 37 were non-patient donors who did not receive therapeutic intervention, and therefore, no outcome data was collected."}